Carvana Co vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Carvana Co trades at $64.21 (market cap $69.55B), while Nuvation Bio Inc. Class A Common Stock trades at $4.96 (market cap $1.74B). The key difference: Carvana Co is far larger — about 40× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is more actively traded (9,289,619 versus 7,671,750). Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| CVNA | NUVB | |
|---|---|---|
Market Cap | $69.55B | $1.74B |
Volume | 7,671,750 | 9,289,619 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $9.54 |
52-Week Low | $56.27 | $3.41 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $72.04B | $1.33B |
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $64.26, up 2.39% on the day, showing resilience amid a bearish technical signal. The company reported strong revenue growth to $20.32B in 2025 with net income of $1.41B, and has beaten EPS estimates for three consecutive quarters. Positive analyst sentiment is highlighted by a consensus price target of $84.07, though technical indicators suggest near-term caution with key support at $61.
Outlook remains positive due to robust earnings beats and expansion initiatives, but risks include high debt levels and competitive pressures. The stock offers growth potential if operational execution continues, yet investors should monitor cash flow sustainability and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →